other material
confidence high
sentiment positive
materiality 0.85
Altimmune Phase 1b pemvidutide: 68.5% liver fat reduction, 4.9% weight loss at 12 weeks
Altimmune, Inc.
- At 1.8 mg dose, relative liver fat reduction of 68.5%; 94.4% of subjects achieved ≥30% reduction.
- Mean weight loss of 4.9% in non-diabetic subjects (placebo-adjusted 4.7%) at 1.8 mg dose.
- 55.6% of subjects at 1.8 mg achieved liver fat normalization (≤5%).
- No serious or severe adverse events; 2 discontinuations due to GI intolerance.
- Serum ALT declined >17 IU/L in subjects with baseline ALT ≥30 IU/L; no clinically significant ALT elevations.